Cambridge Epigenetix (CEGX) is a life sciences tools and analytics company, founded in 2012, by Professor Sir Shankar Balasubramanian FRS and Dr. Bobby Yerramilli-Rao. CEGX is seeking to revolutionize genome sequencing through a proprietary technology platform that has the potential to deliver step changes in both the type of information that can be generated from DNA and the cost at which it is gathered. This is bringing closer the day when advanced medicines, diagnostics and personalized treatments become a reality for all
The Cambridge Epigenetix platform, extends the information content of sequencing by unambiguously identifying five letters of DNA – four genetic bases (A-T-C-G) plus methylated cytosine (5mC or 5hmC). This information is captured at single base resolution from very small amounts of DNA, and with an accuracy that exceeds other known methods. This approach can significantly reduce sequencing costs whilst preserving complexity, facilitating rapid and lower cost data analysis.
Epigenetic marks are a vital source of biological information to enable the next generation of diagnostics including those for early cancer detection. The laboratory component of CEGX’s product is already in manufacture and kits, with associated software, are expected to be available in early 2022. This will be followed by the launch of additional multiomic products from this platform, the next being a 6-letter kit’ (adding the epigenetic marker hydroxymethylcytosine). CEGX is developing further technology platforms supported by their extensive IP portfolio.
In late 2021, the JIMCO Life Sciences Fund participated in Cambridge Epigenetix’s US$ 88 million Series D funding round.
Easily integrating into existing sequencers, the company’s products allow the user to see at-a-glance genomic and epigenetic information. Such information can be employed to detect, diagnose, treat and understand disease. Based in Cambridge, UK, the company is founded by a pioneer in DNA sequencing intent on leading the next great leap forward in genomics.
News from our Portfolio Businesses
The brands and business in the JIMCO investment portfolio are making the news around the world as their transformational approach to global challenges is enabling all of us to take steps towards a more beautiful tomorrow.
You can catch-up with some of their latest headlines here:
Now available for download! Read our recent poster: “In...
Fragmentomics— what? Cell-free DNA (cfDNA) has emerged...
There is a first for everything! We are delighted to
What is epigenetics? A brief introduction into how & wh...
We love a good infographic, and of course we love
How liquid biopsy is transforming neurodegenerative dis...
An incredible insight into some truly groundbreaking re...
We are thrilled to be included in this piece by
“A new sequencing technology reveals not only what info...
Excited to see this out! “A new sequencing technology...
Liquid biopsy is poised to redefine the way we approach
DNA contains molecular information encoded in both gene...
The Cambridge Epigenetics Summer Symposium at The Babra...
Dan Brudzewsky in action at the University of Cambridge...
The power of epigenetic information is exemplified in t...
What is the 6-base genome? Genetics does not tell the
What is DNA methylation and how does it play a
The biomodal team is excited to announce our strategic ...
hashtag#BreakingNews: Today we announce we’re deliverin...
We are excited to announce the appointment of Dr. Peter
????Want to learn how to generate high-quality #genomic...
It is now possible to accurately measure epigenetic met...
It is now possible to interrogate epigenetic and geneti...
It’s now possible to obtain complete genetic and modifi...
Having both genetic and epigenetic information on the s...
Could DNA methylation be used as a potential biomarker ...
Watch the full interview with our Senior Director of Co...
ICYMI: It is now possible to accurately measure epigene...
A study of pancreatic tumorigenesis in Science Magazine...
Heard of the duet multiomics solution +modC, but not su...
Empirically observed phred scores are >Q40 for A and G
The genetic alphabet is more than just A,C,G,T. duet mu...
It is now possible to accurately measure epigenetic met...
ICYMI: Our co-founder, Prof. Sir Shankar Balasubramania...
A study of pancreatic tumorigenesis in Science Magazine...
Epigenetic clocks, aging and cancer.Great review from S...
CEGX in attendance for the Epigenetics & Epigenomics in...
Want to know why epigenetics is potentially so impactfu...
Our CSO, Joanna Holbrook, on this week’s PMF podcast di...
For all of you non-scientists out there, the CDC gives
Epigenome-wide DNA methylation patterns in convalescent...
Exciting news – Lifting the lid on our technology!Paper...
Join Cambridge Epigenetix’ co-founder Professor Shankar...
Announcing the signing of an $88 million Series D finan...
Have you seen the #BIAFinanceReport yet?
Important note: these news items are links to external third-party content and will open in a new tab. These links are provided for your information only. JIMCO has, unless explicitly indicated otherwise, no control over the content of those sites or resources and has no rights in the content of those sites or in the resources. JIMCO assumes no responsibility for the content of websites linked on the JIMCO Website. Such links should not be interpreted as endorsement by JIMCO nor Abdul Latif Jameel of those linked websites therein.
Explore other partners
